Desarrollo de las lágrimas artificiales sin preservo, solución oftálmica
Palavras-chave:
hipromelosa; lágrima artificial; monodosis; síndrome del ojo seco; solución oftálmica.Resumo
Translator
Referências
1. LIEVENS, C.; BERDY, G.; DOSUGLASS, D.; MONTAQUILA, S.; LIN, H.; SIMMONS, P.; ET AL. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. Contac Lens and Anterior Eye. 2019, 42, p. 443-449. https://doi.org/10.1016/j.clae.2018.12.003
2. FARRAND, K.F.; FRIDMAN, M.; STILLMAN, I.O.; SCHAUMBERG, D.A. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017, 182, p. 90-98. DOI: 10.1016/j.ajo.2017.06.033
3. WAN, Y.; ZHANG, M.; LI, X. The global prevalence of dry eye disease and its association with economy: a systematic review. Preprint from Research Square. 2019. https://doi.org/10.21203/rs.2.10986/v1
4. WENG, J.; FINK, M.K.; SHARMA, A. A critical appraisal of the physicochemical properties and biological effects of artificial tear ingredients and formulations. Int. J. Mol. Sci. 2023, 24(3), 2758. https://doi.org/10.3390/ijms24032758
5. AARTHI, S.; AKASH, M.; UMADEVI, S. Formulation of artificial tears nano emulsion and assessment of stability. Eur. Chem. Bull. 2023, 12(8), p. 4501-4513. https://www.researchgate.net/publication/379484437
6. KUMAR, P.; SINGH, P. Formulation and evaluation of eye drop for dry eye syndrome. Int. J. Pharma. Res. Health Sci. 2018, 6(2), p. 2410-12. DOI:10.21276/ijprhs.2018.2018.02.12
7. ABUSHARHA, A.; PEARCE, I.E.; AFSAR, T.; RAZAK, S. Evaluation of therapeutic capability of emustil drops against tear film complications under dry environmental conditions in healthy individuals. Medicina. 2023, 59, 1298. https://doi.org/10.3390/medicina59071298
8. CHE ARIF, F.A.; HILMI, M.R.; MOHD KAMAL, K.; ITHNIN, M.H. Evaluation of 18 artificial tears based on viscosity and pH. Malaysian Journal of Ophthalmology. 2020, 2, p. 96-111. DOI: 10.35119/myjo.v2i2.109
9. CHE ARIF, F.A.; HILMI, M.R.; MOHD KAMAL, K.; ITHNIN, M.H. Comparison of immediate effects on usage of dual polymer artificial tears on changes in tear film characteristics. Malaysian Journal of of Medicine and Health Sciences. 2021, 17(3), p. 252-258. (eISSN 2636-9346)
10. RIBEIRO, M.V.M.R.; BARBOSA, F.T.; RIBEIRO, L.E.F.; DE SOUSA-RODRIGUES, C.F.; NOGUEIRA RIBEIRO, E.A. Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review. Arq Bras Oftalmol. 2019, 82(5), p. 436-45. http://dx.doi.org/10.5935/0004-2749.20190097
11. SEMP, D.A.; BEESON, D.; SHEPPARD, A.L.; DUTTA, D.; WOLFFSOHN, J.S. Artificial tears: A systematic review. Clinical Optometry. 2023, 15, p. 9-27. https: //doi.org/10.2147/OPTO.S350185
12. WALSH, K.; JONES, L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019, 13, p.1409–1425. DOI:10.2147/opth.S21161
13. ARAGONA, P.; SIMMONS, P.A.; WANG, H., WANG, T. Physicochemical properties of hyaluronic acid-based lubricant eye drops. Transl Vis Sci Technol. 2019, 8(6), p. 2. DOI:10.1167/tvst.8.6.2
14. SAVIĆ, V.; ŽIVKOVIĆ, J.; STANKOVIĆ, M.; ANTUNOVIĆ, M.; BASIĆ, Z.; NIKOLIĆ, I. The influence of excipients on stability of viscous eye drops with dexpanthenol in pharmaceutical practice. Acta Poloniae Pharmaceutica - Drug Research. 2019, 76(5), p. 845-853. DOI: 10.32383/appdr/109202
15. AGARWAL, P.; CRAIG, J.P.; RUPENTHAL, I.D. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021, 13(2), 207. DOI:10.3390/pharmaceutics13020207
16. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). Anexo No. 04 Buenas Prácticas de Fabricación de Productos Estériles. Regulación No. 16-2012: Directrices de Buenas Prácticas de Fabricación de Productos Farmacéuticos. Ministerio de Salud Pública: La Habana, Cuba. 2012, p. 108-138.
17. PEÑA ROCHE, Y.l. Desarrollo de las lágrimas artificiales, solución oftálmica, sin preservo. Tesis presentada en opción al título de Máster en Tecnología y Control de Medicamentos. Instituto de Farmacia y Alimentos, Universidad de La Habana, Cuba, 2024.
18. INSTRUCCIÓN DE TRABAJO (INS): INS-PP8-001: Operaciones preliminares para la formulación de productos. UEB Julio Trigo. Cuba. 2021.
19. PROCEDIMIENTO NORMALIZADO de OPERACIÓN (PNO): PNO-PP5-013: Prueba de integridad a las membranas filtrantes mediante el equipo Sartocheck 4 Plus. UEB Julio Trigo. Cuba. 2021.
20. United States Pharmacopeia 40 Ed. (USP 40). United States Pharmacopoeia. US Pharmacopoeia Convention, Inc. Washington DC. 2017, p. 155, 715, 719, 871, 872, 2722, 5013-5016. https://www.uspnf.com/official-text/proposal-statuscommentary/usp-40-nf-35
21. PROCEDIMIENTO NORMALIZADO de OPERACIÓN (PNO): PNO-FQ6-014: Ensayo de viscosidad. UEB Julio Trigo. Cuba, 2022.
2. FARRAND, K.F.; FRIDMAN, M.; STILLMAN, I.O.; SCHAUMBERG, D.A. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017, 182, p. 90-98. DOI: 10.1016/j.ajo.2017.06.033
3. WAN, Y.; ZHANG, M.; LI, X. The global prevalence of dry eye disease and its association with economy: a systematic review. Preprint from Research Square. 2019. https://doi.org/10.21203/rs.2.10986/v1
4. WENG, J.; FINK, M.K.; SHARMA, A. A critical appraisal of the physicochemical properties and biological effects of artificial tear ingredients and formulations. Int. J. Mol. Sci. 2023, 24(3), 2758. https://doi.org/10.3390/ijms24032758
5. AARTHI, S.; AKASH, M.; UMADEVI, S. Formulation of artificial tears nano emulsion and assessment of stability. Eur. Chem. Bull. 2023, 12(8), p. 4501-4513. https://www.researchgate.net/publication/379484437
6. KUMAR, P.; SINGH, P. Formulation and evaluation of eye drop for dry eye syndrome. Int. J. Pharma. Res. Health Sci. 2018, 6(2), p. 2410-12. DOI:10.21276/ijprhs.2018.2018.02.12
7. ABUSHARHA, A.; PEARCE, I.E.; AFSAR, T.; RAZAK, S. Evaluation of therapeutic capability of emustil drops against tear film complications under dry environmental conditions in healthy individuals. Medicina. 2023, 59, 1298. https://doi.org/10.3390/medicina59071298
8. CHE ARIF, F.A.; HILMI, M.R.; MOHD KAMAL, K.; ITHNIN, M.H. Evaluation of 18 artificial tears based on viscosity and pH. Malaysian Journal of Ophthalmology. 2020, 2, p. 96-111. DOI: 10.35119/myjo.v2i2.109
9. CHE ARIF, F.A.; HILMI, M.R.; MOHD KAMAL, K.; ITHNIN, M.H. Comparison of immediate effects on usage of dual polymer artificial tears on changes in tear film characteristics. Malaysian Journal of of Medicine and Health Sciences. 2021, 17(3), p. 252-258. (eISSN 2636-9346)
10. RIBEIRO, M.V.M.R.; BARBOSA, F.T.; RIBEIRO, L.E.F.; DE SOUSA-RODRIGUES, C.F.; NOGUEIRA RIBEIRO, E.A. Effectiveness of using preservative-free artificial tears versus preserved lubricants for the treatment of dry eyes: a systematic review. Arq Bras Oftalmol. 2019, 82(5), p. 436-45. http://dx.doi.org/10.5935/0004-2749.20190097
11. SEMP, D.A.; BEESON, D.; SHEPPARD, A.L.; DUTTA, D.; WOLFFSOHN, J.S. Artificial tears: A systematic review. Clinical Optometry. 2023, 15, p. 9-27. https: //doi.org/10.2147/OPTO.S350185
12. WALSH, K.; JONES, L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019, 13, p.1409–1425. DOI:10.2147/opth.S21161
13. ARAGONA, P.; SIMMONS, P.A.; WANG, H., WANG, T. Physicochemical properties of hyaluronic acid-based lubricant eye drops. Transl Vis Sci Technol. 2019, 8(6), p. 2. DOI:10.1167/tvst.8.6.2
14. SAVIĆ, V.; ŽIVKOVIĆ, J.; STANKOVIĆ, M.; ANTUNOVIĆ, M.; BASIĆ, Z.; NIKOLIĆ, I. The influence of excipients on stability of viscous eye drops with dexpanthenol in pharmaceutical practice. Acta Poloniae Pharmaceutica - Drug Research. 2019, 76(5), p. 845-853. DOI: 10.32383/appdr/109202
15. AGARWAL, P.; CRAIG, J.P.; RUPENTHAL, I.D. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021, 13(2), 207. DOI:10.3390/pharmaceutics13020207
16. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). Anexo No. 04 Buenas Prácticas de Fabricación de Productos Estériles. Regulación No. 16-2012: Directrices de Buenas Prácticas de Fabricación de Productos Farmacéuticos. Ministerio de Salud Pública: La Habana, Cuba. 2012, p. 108-138.
17. PEÑA ROCHE, Y.l. Desarrollo de las lágrimas artificiales, solución oftálmica, sin preservo. Tesis presentada en opción al título de Máster en Tecnología y Control de Medicamentos. Instituto de Farmacia y Alimentos, Universidad de La Habana, Cuba, 2024.
18. INSTRUCCIÓN DE TRABAJO (INS): INS-PP8-001: Operaciones preliminares para la formulación de productos. UEB Julio Trigo. Cuba. 2021.
19. PROCEDIMIENTO NORMALIZADO de OPERACIÓN (PNO): PNO-PP5-013: Prueba de integridad a las membranas filtrantes mediante el equipo Sartocheck 4 Plus. UEB Julio Trigo. Cuba. 2021.
20. United States Pharmacopeia 40 Ed. (USP 40). United States Pharmacopoeia. US Pharmacopoeia Convention, Inc. Washington DC. 2017, p. 155, 715, 719, 871, 872, 2722, 5013-5016. https://www.uspnf.com/official-text/proposal-statuscommentary/usp-40-nf-35
21. PROCEDIMIENTO NORMALIZADO de OPERACIÓN (PNO): PNO-FQ6-014: Ensayo de viscosidad. UEB Julio Trigo. Cuba, 2022.
Downloads
Publicado
2025-03-20
Como Citar
Peña-Roche, Y. L., Ramírez-Torres, G., Madrazo-Alonso, O., Fernández-Cervera, M., & Romeu-Carballo, C. R. (2025). Desarrollo de las lágrimas artificiales sin preservo, solución oftálmica. Tecnologia Química, 45, 81–95. Recuperado de https://tecnologiaquimica.uo.edu.cu/index.php/tq/article/view/5447
Edição
Seção
Artículos
Licença
Este trabalho está licenciado sob a Licença Creative Commons CC-BY-NC-ND
Universidad de Oriente 